AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease

Abraham Fisher, Ilya Bezprozvanny, Lili Wu, Daniel A. Ryskamp, Nira Bar-Ner, Niva Natan, Rachel Brandeis, Hanoch Elkon, Victoria Nahum, Eitan Gershonov, Frank M. LaFerla, Rodrigo Medeiros

Research output: Contribution to journalArticle

17 Scopus citations

Abstract

We previously developed orthosteric M1 muscarinic agonists (e.g. AF102B, AF267B and AF292), which act as cognitive enhancers and potential disease modifiers. We now report on a novel compound, AF710B, a highly potent and selective allosteric M1 muscarinic and σ1 receptor agonist. AF710B exhibits an allosteric agonistic profile on the M1 muscarinic receptor; very low concentrations of AF710B significantly potentiated the binding and efficacy of carbachol on M1 receptors and their downstream effects (p-ERK1/2, p-CREB). AF710B (1-30 μg/kg, p.o.) was a potent and safe cognitive enhancer in rats treated with the M1 antagonist trihexyphenidyl (passive avoidance impairment). These effects of AF710B involve σ1 receptor activation. In agreement with its antiamnesic properties, AF710B (at 30 nM), via activation of M1 and a possible involvement of σ1 receptors, rescued mushroom synapse loss in PS1-KI and APP-KI neuronal cultures, while AF267B (1 μM) was less potent in PS1-KI and ineffective in APP-KI models, respectively. In female 3xTg-AD mice, AF710B (10 μg/kg, i.p./daily/2 months) (i) mitigated cognitive impairments in the Morris water maze; (ii) decreased BACE1, GSK3β activity, p25/CDK5, neuroinflammation, soluble and insoluble Aβ40, Aβ42, plaques and tau pathologies. AF710B differs from conventional σ1 and M1 muscarinic (orthosteric, allosteric or bitopic) agonists. These results highlight AF710B as a potential treatment for Alzheimer's disease (e.g. improving cognitive deficits, synaptic loss, amyloid and tau pathologies, and neuroinflammation) with a superior profile over a plethora of other therapeutic strategies.

Original languageEnglish (US)
Pages (from-to)95-110
Number of pages16
JournalNeurodegenerative Diseases
Volume16
Issue number1-2
DOIs
StatePublished - Feb 1 2016

Keywords

  • AF series
  • AF267B
  • AF710B
  • Alzheimer's disease
  • Amyloids
  • Cognitive deficits
  • Disease modification
  • M1 muscarinic acetylcholine receptor
  • Memory
  • Neuroinflammation
  • Tau protein
  • σ1 receptor

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology

Fingerprint Dive into the research topics of 'AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease'. Together they form a unique fingerprint.

  • Cite this

    Fisher, A., Bezprozvanny, I., Wu, L., Ryskamp, D. A., Bar-Ner, N., Natan, N., Brandeis, R., Elkon, H., Nahum, V., Gershonov, E., LaFerla, F. M., & Medeiros, R. (2016). AF710B, a novel M1/σ1 agonist with therapeutic efficacy in animal models of Alzheimer's disease. Neurodegenerative Diseases, 16(1-2), 95-110. https://doi.org/10.1159/000440864